Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Initial Experience With the AngioVac Venous Drainage Cannula
Initial Experience With the AngioVac Venous Drainage Cannula and Cardiopulmonary Bypass Circuit: A Retrospective, Multi-Center Chart Review
Status: Enrolling
Updated:  12/6/2017
MUSC
mi
from
Charleston, SC
Initial Experience With the AngioVac Venous Drainage Cannula
Initial Experience With the AngioVac Venous Drainage Cannula and Cardiopulmonary Bypass Circuit: A Retrospective, Multi-Center Chart Review
Status: Enrolling
Updated: 12/6/2017
MUSC
mi
from
Charleston, SC
Click here to add this to my saved trials
Initial Experience With the AngioVac Venous Drainage Cannula
Initial Experience With the AngioVac Venous Drainage Cannula and Cardiopulmonary Bypass Circuit: A Retrospective, Multi-Center Chart Review
Status: Enrolling
Updated:  12/6/2017
Swedish Health Services
mi
from
Seattle, WA
Initial Experience With the AngioVac Venous Drainage Cannula
Initial Experience With the AngioVac Venous Drainage Cannula and Cardiopulmonary Bypass Circuit: A Retrospective, Multi-Center Chart Review
Status: Enrolling
Updated: 12/6/2017
Swedish Health Services
mi
from
Seattle, WA
Click here to add this to my saved trials
Feasibility of Orbital Atherectomy System in Calcified Bifurcation Lesion
Feasibility of Orbital Atherectomy System in Calcified Bifurcation Lesion
Status: Enrolling
Updated:  12/6/2017
Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital
mi
from
New York, NY
Feasibility of Orbital Atherectomy System in Calcified Bifurcation Lesion
Feasibility of Orbital Atherectomy System in Calcified Bifurcation Lesion
Status: Enrolling
Updated: 12/6/2017
Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Vitamin D and Coronary Calcification Study
A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4
Status: Enrolling
Updated:  12/7/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Vitamin D and Coronary Calcification Study
A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4
Status: Enrolling
Updated: 12/7/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia
Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia
Status: Enrolling
Updated:  12/7/2017
NYU Langone Medical Center
mi
from
New York, NY
Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia
Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia
Status: Enrolling
Updated: 12/7/2017
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)
Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)
Status: Enrolling
Updated:  12/11/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)
Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)
Status: Enrolling
Updated: 12/11/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease
The Intracoronary Tissue-type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events in Patients With Non-critical Coronary Artery Disease
Status: Enrolling
Updated:  12/11/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease
The Intracoronary Tissue-type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events in Patients With Non-critical Coronary Artery Disease
Status: Enrolling
Updated: 12/11/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Platelet Activity in Vascular Surgery for Thrombosis and Bleeding
Platelet Activity in Vascular Surgery
Status: Enrolling
Updated:  12/12/2017
Bellevue Hospital Center, South Manhattan Healthcare Network
mi
from
New York, NY
Platelet Activity in Vascular Surgery for Thrombosis and Bleeding
Platelet Activity in Vascular Surgery
Status: Enrolling
Updated: 12/12/2017
Bellevue Hospital Center, South Manhattan Healthcare Network
mi
from
New York, NY
Click here to add this to my saved trials
Platelet Activity in Vascular Surgery for Thrombosis and Bleeding
Platelet Activity in Vascular Surgery
Status: Enrolling
Updated:  12/12/2017
New York University School of Medicine
mi
from
New York, NY
Platelet Activity in Vascular Surgery for Thrombosis and Bleeding
Platelet Activity in Vascular Surgery
Status: Enrolling
Updated: 12/12/2017
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Status: Enrolling
Updated:  12/12/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Status: Enrolling
Updated: 12/12/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Status: Enrolling
Updated:  12/12/2017
NYU Langone Medical Center
mi
from
New York, NY
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Status: Enrolling
Updated: 12/12/2017
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Status: Enrolling
Updated:  12/12/2017
Univ of Rochester Medical Center
mi
from
Rochester, NY
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Status: Enrolling
Updated: 12/12/2017
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Status: Enrolling
Updated:  12/12/2017
Nova Scotia Health Authority
mi
from
Halifax,
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3
Status: Enrolling
Updated: 12/12/2017
Nova Scotia Health Authority
mi
from
Halifax,
Click here to add this to my saved trials
SCD Use to Prevent Deep Venous Thrombosis (DVT) in Patients With PICC Lines
Sequential Pneumatic Compression to Prevent PICC-related Upper Extremity Venous Thrombosis in Critically Ill Neurological Patients
Status: Enrolling
Updated:  12/12/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
SCD Use to Prevent Deep Venous Thrombosis (DVT) in Patients With PICC Lines
Sequential Pneumatic Compression to Prevent PICC-related Upper Extremity Venous Thrombosis in Critically Ill Neurological Patients
Status: Enrolling
Updated: 12/12/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Using Capnography to Reduce Hypoxia During Pediatric Sedation
Using Capnography to Reduce the Incidence of Hypoxia in Children During Moderate Sedation in the Pediatric Emergency Department: A Randomized Controlled Trial
Status: Enrolling
Updated:  12/13/2017
Yale-New Haven Children's Hospital
mi
from
New Haven, CT
Using Capnography to Reduce Hypoxia During Pediatric Sedation
Using Capnography to Reduce the Incidence of Hypoxia in Children During Moderate Sedation in the Pediatric Emergency Department: A Randomized Controlled Trial
Status: Enrolling
Updated: 12/13/2017
Yale-New Haven Children's Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
CancerCodeTM Informed, Molecularly Targeted Therapies in Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/13/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
CancerCodeTM Informed, Molecularly Targeted Therapies in Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/13/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vitamins in Nitrous Oxide Study
Pharmacogenetics of Adverse Outcomes After Nitrous Oxide Anesthesia
Status: Enrolling
Updated:  12/14/2017
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Vitamins in Nitrous Oxide Study
Pharmacogenetics of Adverse Outcomes After Nitrous Oxide Anesthesia
Status: Enrolling
Updated: 12/14/2017
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
Status: Enrolling
Updated:  12/14/2017
Yale University
mi
from
New Haven, CT
Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
Status: Enrolling
Updated: 12/14/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Beverly Hills, CA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
La Jolla, CA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Ventura, CA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Ventura, CA
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Denver, CO
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Jacksonville, FL
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Columbus, GA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Columbus, GA
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Joliet, IL
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Joliet, IL
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Rockport, ME
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Rockport, ME
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Boston, MA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Boston, MA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Boston, MA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Detroit, MI
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Butte, MT
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Butte, MT
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Raleigh, NC
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Columbus, OH
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Toledo, OH
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
San Antonio, TX
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Fredericksburg, VA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Bellevue, WA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Bellevue, WA
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Seattle, WA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Spokane, WA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated:  12/17/2017
Clinical Research Facility
mi
from
Tacoma, WA
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status: Enrolling
Updated: 12/17/2017
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated:  12/18/2017
University of Arizona
mi
from
Tucson, AZ
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated: 12/18/2017
University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated:  12/18/2017
Emory University
mi
from
Atlanta, GA
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated: 12/18/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated:  12/18/2017
Rockford Memorial Hospital
mi
from
Rockford, IL
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated: 12/18/2017
Rockford Memorial Hospital
mi
from
Rockford, IL
Click here to add this to my saved trials
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated:  12/18/2017
Massachusetts General Hospital
mi
from
Boston, MA
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated: 12/18/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated:  12/18/2017
Ohio State University
mi
from
Columbus, OH
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated: 12/18/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated:  12/18/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated: 12/18/2017
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated:  12/18/2017
Sentara Heart Hospital
mi
from
Norfolk, VA
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated: 12/18/2017
Sentara Heart Hospital
mi
from
Norfolk, VA
Click here to add this to my saved trials
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated:  12/18/2017
Arizona Heart Hospital
mi
from
Phoenix, AZ
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies
Status: Enrolling
Updated: 12/18/2017
Arizona Heart Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials